What is HC Wainwright's Estimate for CRVS Q4 Earnings?

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Investment analysts at HC Wainwright issued their Q4 2024 earnings estimates for Corvus Pharmaceuticals in a research report issued to clients and investors on Thursday, January 2nd. HC Wainwright analyst S. Lee forecasts that the company will earn ($0.12) per share for the quarter. HC Wainwright has a "Buy" rating and a $11.00 price target on the stock. The consensus estimate for Corvus Pharmaceuticals' current full-year earnings is ($0.68) per share. HC Wainwright also issued estimates for Corvus Pharmaceuticals' FY2029 earnings at $0.49 EPS.

CRVS has been the topic of several other research reports. Oppenheimer upped their price objective on shares of Corvus Pharmaceuticals from $8.00 to $14.00 and gave the stock an "outperform" rating in a report on Wednesday, November 13th. LADENBURG THALM/SH SH lifted their target price on Corvus Pharmaceuticals from $12.00 to $21.00 and gave the company a "buy" rating in a research report on Monday, September 16th. StockNews.com cut Corvus Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Thursday, October 31st. Finally, Mizuho raised shares of Corvus Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, October 22nd. One investment analyst has rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $12.38.

Corvus Pharmaceuticals Stock Performance

Corvus Pharmaceuticals stock traded up $0.40 during mid-day trading on Friday, reaching $5.83. The stock had a trading volume of 802,498 shares, compared to its average volume of 856,299. Corvus Pharmaceuticals has a fifty-two week low of $1.30 and a fifty-two week high of $10.00. The stock's 50-day simple moving average is $7.67 and its 200-day simple moving average is $5.29. The firm has a market capitalization of $374.62 million, a PE ratio of -6.27 and a beta of 1.05.

Institutional Investors Weigh In On Corvus Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of CRVS. Samlyn Capital LLC raised its position in shares of Corvus Pharmaceuticals by 160.7% in the second quarter. Samlyn Capital LLC now owns 6,123,021 shares of the company's stock worth $11,144,000 after buying an additional 3,774,658 shares in the last quarter. Marshall Wace LLP purchased a new stake in shares of Corvus Pharmaceuticals in the 2nd quarter valued at about $136,000. Cubist Systematic Strategies LLC bought a new stake in Corvus Pharmaceuticals during the second quarter valued at approximately $44,000. Point72 Asset Management L.P. bought a new stake in shares of Corvus Pharmaceuticals during the 2nd quarter worth $10,855,000. Finally, Avity Investment Management Inc. increased its stake in Corvus Pharmaceuticals by 138.2% in the third quarter. Avity Investment Management Inc. now owns 27,580 shares of the company's stock valued at $146,000 after acquiring an additional 16,000 shares during the last quarter. 46.64% of the stock is owned by hedge funds and other institutional investors.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.